Profile: Dr.Reddy's Laboratories Ltd (RDY)
27 Feb 2015
Dr.Reddy's Laboratories Ltd, incorporated on February 24, 1984, is an India-based integrated global pharmaceutical company that provides medicines. The Company derives its revenue from the sale of finished dosage forms, active pharmaceutical ingredients and intermediates, development and manufacturing services provided to pharmaceutical and biotechnology companies, and license fees from marketing authorizations for its proprietary products. Its presence in science and technology ranges from synthetic organic chemistry, formulation development, biologics development and small molecule based drug discovery. The Company has three reportable segments Global Generics, Pharmaceutical Services and Active Ingredients (PSAI) and Proprietary Products.
This segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company’s biologics business. The segment is divided in branded and unbranded Global Generics segment.
Pharmaceutical Services and Active Ingredients (PSAI
This segment includes active pharmaceutical ingredients and intermediates, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption, such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with specific customer requirements. The Company’s Pharmaceutical Services and Active Ingredients segment is comprised of the Company’s Active Pharmaceutical Ingredients (API) business and its Custom Pharmaceutical Services (CPS). Its product offerings in the API business are positioned to offer intellectual property and technology advantaged products to enable launches ahead of others at competitive prices. Its CPS business, offers niche product service capabilities and technology platforms.
This segment includes the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. The Company’s differentiated formulations portfolio consists of new, synergistic combinations and technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment also includes its specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The Company’s Proprietary Products business is comprised of its Differentiated Formulations business, which focuses on meeting unmet medical needs by investigating new dosage forms and indications for existing medicines as well as new combination products and technologies that improve safety and/or efficacy by improving pharmacokinetics; New Chemical Entity (“NCE”) research business, which is focused on the discovery, development and commercialization of novel small molecule agents in therapeutic areas such as anti-infectives, metabolic disorders, and pain and inflammation; and dermatology focused Specialty business, which has a portfolio of in-licensed patented dermatology products and off-patent cardiovascular products.
Dr.Reddy's Laboratories Ltd
Road No.3, BANJARA HILLS, Telang